{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047568","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.823633+00:00","generated_at":"2026-05-21T13:21:13.424371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cellectar Biosciences Q1 2025 Net Loss Narrowed to $6.6M; Seeks EMA Conditional Approval for Iopofosine","bullets":["Net loss for Q1 2025 was $6.6 million ($0.14 per share), compared to $26.6 million ($0.91 per share) in Q1 2024.","Company seeking conditional EMA approval for iopofosine I 131 in Waldenstrom macroglobulinemia based on CLOVER WaM Phase 2 data with 59% major response rate in BTKi-treated patients.","Cash and cash equivalents totaled $13.9 million as of March 31, 2025, expected to fund operations into Q4 2025.","Board engaged Oppenheimer & Co. as exclusive financial advisor to explore strategic alternatives including mergers, acquisitions, or partnerships.","Planned Phase 3 study for iopofosine I 131 would be a comparator randomized controlled study with 100 patients per arm, dependent on funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047568","json":"https://secwatch.observer/filing/0001104659-25-047568.json","markdown":"https://secwatch.observer/filing/0001104659-25-047568.md","text":"https://secwatch.observer/filing/0001104659-25-047568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/0001104659-25-047568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925047568/tm2514904d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-21T13:21:13.424371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}